Study Summary
This trial is a prospective, randomized clinical trial in patients undergoing ablation for symptomatic persistent AF to assess whether adding OPTIMA ablation to PVI improves freedom from AF.
- Chronic Atrial Fibrillation
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 1 year
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Standard Ablation (PVI)
1 of 2
OPTIMA Ablation
1 of 2
Active Control
Experimental Treatment
200 Total Participants · 2 Treatment Groups
Primary Treatment: OPTIMA Ablation · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To what extent is the sample size being utilized in this medical study?
"Indeed, clinicaltrials.gov displays that this study is currently enrolling volunteers. This trial was published on September 1st 2019 and has been revised as recently as 9/26/2022. 200 individuals across one medical site are required to fulfill the enrolment goals of this research project." - Anonymous Online Contributor
Are there any openings for participants in this trial currently?
"According to clinicaltrials.gov, this trial is in need of participants and has been since September 1st 2019. The study was most recently updated on the 26th of September 2022." - Anonymous Online Contributor